...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: BET inhibitors promising therapy for rare pediatric brain tumor

BDAZ - thank you for posting these articles. This is getting scary for a guy with no scientific background to almost understand what they are talking about.

I found it interesting that in the Nature Medicine Letter that the article was received 30 Nov 2016, accepted 30 Jan 2017 and published 27 Feb 2017. My understanding is that this time from submission to the time of being published is almost like lightening speed for this process to happen.

We are still waiting for a couple of articles to be published for both Zenith and RVX that were submitted last year.

tada

Share
New Message
Please login to post a reply